Pfizer’s Duchenne muscular dystrophy trial fails to meet primary goal
Pfizer’s investigations on gene therapy for patients with Duchenne muscular dystrophy failed to meet its primary goals, according to a company statement.
Drugs
Health
Pharma
Drugs
Medical
Pharma
FDA approves Santhera’s Agamree for Duchenne muscular dystrophy
HQ team October 31, 2023: The US Food and Drug Administration (FDA) has given the green light to Santhera Pharmaceuticals’ drug, Agamree (vamorolone),.